Weight-loss drug cleared by FDA panel
Tuesday, December 7, 2010 - 22:00
in Health & Medicine
Advisors recommend the approval of Contrave despite concerns about its safety — particularly its impact on blood pressure — and effectiveness.An advisory panel to the Food and Drug Administration set aside lingering concerns about the safety and marginal effectiveness of the latest weight-loss drug to come before it, voting 13 to 7 on Tuesday to recommend the approval of Contrave, a combination of two medications available since the mid-1980s — the antidepressant and smoking cessation drug bupropion and the anti- addiction medication naltrexone.
